Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
You may also be interested in...
Qiagen’s doubled-down focus on PCR technologies in late 2019 proved to be fortuitous, but future growth will come from many other drivers, says CFO Roland Sackers.
The diagnostics company said the test is scheduled for US launch in Q4 2020.
Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.